Literature DB >> 19892897

The metabolic syndrome: common origins of a multifactorial disorder.

K D Bruce1, C D Byrne.   

Abstract

The metabolic syndrome (MetS) represents a combination of cardiometabolic risk determinants including obesity (central adiposity), insulin resistance, glucose intolerance, dyslipidaemia, non-alcoholic fatty liver disease and hypertension. MetS is rapidly increasing in prevalence worldwide as a consequence of the continued obesity "epidemic", and as a result will have a considerable impact on the global incidence of cardiovascular disease and type 2 diabetes. Currently, there is debate concerning whether the risk of cardiovascular disease is greater in patients diagnosed with MetS than that of the sum of the individual risk factors. At present, no unifying origin that can explain the pathogenesis of MetS has been identified and therefore no unique pharmacological treatment is available. This review summarises and critically evaluates the current clinical and scientific evidence supporting the existence of MetS as a multifactorial endocrine disease, for which maternal nutrition may be a common pathogenic mechanism. In addition, we suggest that ectopic fat accumulation (such as visceral and hepatic fat accumulation) and the proinflammatory state are central to the development of the MetS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19892897     DOI: 10.1136/pgmj.2008.078014

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  45 in total

1.  Insulin resistance is not necessarily an essential element of metabolic syndrome.

Authors:  Rudruidee Karnchanasorn; Horng-Yi Ou; Lee-Ming Chuang; Ken C Chiu
Journal:  Endocrine       Date:  2012-05-29       Impact factor: 3.633

Review 2.  Central obesity and nonalcoholic fatty liver disease risk after adjusting for body mass index.

Authors:  Qing Pang; Jing-Yao Zhang; Si-Dong Song; Kai Qu; Xin-Sen Xu; Su-Shun Liu; Chang Liu
Journal:  World J Gastroenterol       Date:  2015-02-07       Impact factor: 5.742

3.  Syndrome of insulin resistance with acanthosis nigricans, acral hypertrophy and muscle cramps in an adolescent - a rare diagnosis revisited.

Authors:  Urmi Ghosh; Maya Thomas; Sarah Mathai
Journal:  Indian J Pediatr       Date:  2014-06-10       Impact factor: 1.967

4.  Sodium perchlorate induces non-alcoholic fatty liver disease in developing stickleback.

Authors:  Michael R Minicozzi; Frank A von Hippel; Christoff G Furin; C Loren Buck
Journal:  Environ Pollut       Date:  2019-05-02       Impact factor: 8.071

Review 5.  Molecular mechanisms for insulin resistance in treated HIV-infection.

Authors:  Paul W Hruz
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2011-06       Impact factor: 4.690

6.  AMPK mediates the initiation of kidney disease induced by a high-fat diet.

Authors:  Anne-Emilie Declèves; Anna V Mathew; Robyn Cunard; Kumar Sharma
Journal:  J Am Soc Nephrol       Date:  2011-09-15       Impact factor: 10.121

Review 7.  Areca-nut chewing habit is a significant risk factor for metabolic syndrome: a systematic review.

Authors:  F Javed; K Al-Hezaimi; S Warnakulasuriya
Journal:  J Nutr Health Aging       Date:  2012-05       Impact factor: 4.075

8.  Effects of high-fat diet and losartan on renal cortical blood flow using contrast ultrasound imaging.

Authors:  Anne-Emilie Declèves; Joshua J Rychak; Dan J Smith; Kumar Sharma
Journal:  Am J Physiol Renal Physiol       Date:  2013-09-18

9.  Association of the components of the metabolic syndrome with non-alcoholic fatty liver disease among normal-weight, overweight and obese children and adolescents.

Authors:  Roya Kelishadi; Stephen R Cook; Atoosa Adibi; Zahra Faghihimani; Shohreh Ghatrehsamani; Abolfazl Beihaghi; Hamidreza Salehi; Noushin Khavarian; Parinaz Poursafa
Journal:  Diabetol Metab Syndr       Date:  2009-12-22       Impact factor: 3.320

Review 10.  Maternal and in utero determinants of type 2 diabetes risk in the young.

Authors:  Kimberley D Bruce
Journal:  Curr Diab Rep       Date:  2014-01       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.